Literature DB >> 8201328

Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump.

V Patterson1, M Watt, D Byrnes, D Crowe, A Lee.   

Abstract

Intrathecal baclofen abolishes spasticity in many patients with neurological diseases but there are few studies on its long-term effectiveness. Since 1986 a manually operated subcutaneous pump has been used to deliver baclofen intrathecally in 21 patients with a follow up of at least one year. Most patients had multiple sclerosis and all were wheelchair-bound. Sixteen patients had a complete and sustained benefit. In four other patients the treatment was effective in the short term but not in the long term. In the remaining patient the pump never worked. Complications included meningitis, pump failure, erosion through the skin, and baclofen overdose. Nevertheless, only three patients have asked to discontinue the treatment. We conclude that intrathecal baclofen, delivered by a manually operated implanted pump, is an effective treatment for severe spasticity in most patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8201328      PMCID: PMC1072919          DOI: 10.1136/jnnp.57.5.582

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.

Authors:  B ASHWORTH
Journal:  Practitioner       Date:  1964-04

2.  Spinal versus intraventricular chronic opiate administration with implantable drug delivery devices for cancer pain.

Authors:  Y Lazorthes; J C Verdie; R Bastide; A Lavados; D Descouens
Journal:  Appl Neurophysiol       Date:  1985

3.  Intrathecal baclofen alleviates spinal cord spasticity.

Authors:  R D Penn; J S Kroin
Journal:  Lancet       Date:  1984-05-12       Impact factor: 79.321

4.  The formation, structure and analysis of the thermal decomposition product of baclofen.

Authors:  L Borka
Journal:  Acta Pharm Suec       Date:  1979

5.  Intrathecal baclofen for spasticity of spinal origin: seven years of experience.

Authors:  R D Penn
Journal:  J Neurosurg       Date:  1992-08       Impact factor: 5.115

6.  Continuous intrathecal baclofen for severe spasticity.

Authors:  R D Penn; J S Kroin
Journal:  Lancet       Date:  1985-07-20       Impact factor: 79.321

7.  Determination of 4-amino-3-(p-chlorophenyl)butyric acid (baclofen) in plasma by high-performance liquid chromatography.

Authors:  P M Harrison; A M Tonkin; A J McLean
Journal:  J Chromatogr       Date:  1985-05-03

8.  Efficacy of dorsal longitudinal myelotomy in treating spinal spasticity: a review of 20 cases.

Authors:  T K Putty; S A Shapiro
Journal:  J Neurosurg       Date:  1991-09       Impact factor: 5.115

9.  Chronic intrathecal baclofen administration for control of severe spasticity.

Authors:  Y Lazorthes; B Sallerin-Caute; J C Verdie; R Bastide; J P Carillo
Journal:  J Neurosurg       Date:  1990-03       Impact factor: 5.115

  9 in total
  7 in total

Review 1.  Intrathecal baclofen, selective dorsal rhizotomy, and extracorporeal shockwave therapy for the treatment of spasticity in cerebral palsy: a systematic review.

Authors:  Amogh Kudva; Mickey E Abraham; Justin Gold; Neal A Patel; Julian L Gendreau; Yehuda Herschman; Antonios Mammis
Journal:  Neurosurg Rev       Date:  2021-04-19       Impact factor: 3.042

2.  Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system.

Authors:  T J Postma; D Oenema; S Terpstra; J Bouma; H Kuipers-Upmeijer; M J Staal; B J Middel
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

3.  Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity.

Authors:  B Middel; H Kuipers-Upmeijer; J Bouma; M Staal; D Oenema; T Postma; S Terpstra; R Stewart
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

4.  Intrathecal baclofen therapy: complication avoidance and management.

Authors:  Neil Haranhalli; Dhanya Anand; Jeffrey H Wisoff; David H Harter; Howard L Weiner; Michelle Blate; Jonathan Roth
Journal:  Childs Nerv Syst       Date:  2010-09-18       Impact factor: 1.475

5.  Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin.

Authors:  A Zahavi; J H B Geertzen; B Middel; M Staal; J S Rietman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

Review 6.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 7.  Multiple sclerosis therapy. A practical guide.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.